Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine

Seminars in Oncology

Volumn 29, Issue 1, 2002, Pages 62-69

  Baas, Paul ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDROAZACITIDINE; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DETORUBICIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; MENOGARIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRARUBICIN; RALTITREXED; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL TOXICITY; HUMAN; LUNG TOXICITY; MESOTHELIOMA; OTOTOXICITY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0036180739     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30231     Document Type: Article

References (87)

1. Malignant mesothelioma in 1982: Review of 4710 published cases
2. Pathology of malignant mesothelioma
3. Malignant pleural mesothelioma: Value of CT and MRI imaging in predicting resectability
4. Evaluation of pleural diseases with FDG-PET imaging: A prelimanary report
5. Prognostic value of FDG PET imaging in malignant pleural mesothelioma
6. A prospective study of detorubicin in malignant mesothelioma
7. Malignant mesothelioma: The Eastern Cooperative Oncology Group (ECOG) experience
8. Epirubicin treatment of malignant mesothelioma: A phase II cooperative study
9. Epirubicin in malignant mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group
10. Caelyx in malignant mesothelioma: A phase II EORTC study
11. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study
12. Phase II of high-dose cisplatin in patients with malignant mesothelioma
13. Weekly high dose cisplatin in malignant pleural mesothelioma
14. Phase II trial of carboplatin (JM8) in the treatment of patients with malignant mesothelioma
15. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B
16. Phase II trial of carboplatin in the management of malignant mesothelioma
17. Tomudex (Raltitrexed) and eloxatine (Oxaliplatin) is an active combination with acceptable toxicity in malignant mesothelioma
18. Phase II trial of vinorelbine and oxaliplatin (VO) in malignant pleural mesothelioma (MPM)
19. High dose methotrexate with citrovorum and vincristine in the treatment of malignant mesothelioma
20. High dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
21. High dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma
22. Combined treatment of malignant mesothelioma of the pleura with high dose methotrexate and interferon α and γ
23. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B phase II study
24. Edatrexate (10-ethyl-deaza-aminopterin) (NSC: 626715) with or without leukovorin recue for malignant mesothelioma. Sequential phase II trials by the CALGB
25. A phase II study of gemcitabine in patients with malignant pleural mesothelioma
26. Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group
27. Oral etoposide in the treatment of malignant mesothelioma. A phase II study
28. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group
29. High dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234
30. Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group (ECOG 2595)
31. Phase II trial of single agent taxotere (T) in malignant pleural mesothelioma (MPM)
32. Phase II trial of topotecan for the treatment of malignant mesothelioma
33. CPT- 11 in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B
34. Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna
35. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma
36. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study
37. Ifosfamide in malignant mesothelioma: A phase II study
38. Two dose levels of ifosfamide in malignant mesothelioma
39. Studies concerning high dose of ifosfamide in patients suffering from malignant mesothelioma
40. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study
41. Vindesine in the treatment of malignant mesothelioma: A phase II study
42. Phase II trial of vindesine in malignant pleural mesothelioma
43. Phase II study of vinorelbine in patients with malignant pleural mesothelioma
44. A phase II trial of a single weekly intravenous dose of ranpirnase (Onconase) in patients with unresectable malignant mesothelioma
45. Phase III randomized trial of Onconase vs. doxorubicin in patients with unresectable malignant mesothelioma: Analysis of survival
46. Combination chemotherapy with cisplatin, Adriamycin, bleomycin and mitomycin C, plus systemic and intrapleural hyaluronidase in 25 consecutive cases of stage II, III pleural mesothelioma
47. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
48. Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)
49. A phase II study of pirarubicin in malignant pleural mesothelioma
50. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant mesothelioma
51. Phase II study of mitoxantrone in patients with malignant mesothelioma. A National Cancer Institute of Canada Clinical Trial Group study
52. Mitoxantrone in malignant pleural mesothelioma. A study by the EORTC Lung Cancer Cooperative Group
53. Menogaril in the treatment of malignant mesothelioma: A phase II study
54. Phase II trial of mitomycin in malignant mesothelioma
55. N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma
56. Chemotherapy of diffuse malignant mesothelioma: Phase II trials of single agent 5-fluorouracil and Adriamycin
57. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity
58. Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma
59. A phase II study of vincristine in malignant mesothelioma-A negative report
60. A phase II study of M-AMSA in patients with malignant mesothelioma
61. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases
62. Phase II trial of diaziquone in malignant mesothelioma
63. Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus cyclophosphamide and Adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma Intergroup study
64. Combined modality treatment for mesothelioma with Cytoxan and Adriamycin, and DTIC and adjuvant surgery
65. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma
66. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma
67. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study
68. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
69. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma
70. Diffuse malignant mesothelioma: Prospective evaluation of 69 patients
71. Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study
72. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma. A phase II FONICAP trial
73. Treatment of malignant mesothelioma with epirubicin and ifosfamide: A phase II comparative study
74. Combined epirubicin and interleukin 2 regimen in the treatment of malignant mesothelioma: A multicenter phase II study of the Italian Group on Rare Tumors
75. Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: A Southwest Oncology Group study
76. Phase III randomized comparison of pirarubicin vs. pirarubicin and cisplatin for treatment of pleural mesotheliomas. Germany
77. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B
78. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: A pilot phase II clinical trail and pharmacokinetic profile
79. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma
80. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon
81. Cisplatin, mitomycin and interferon α- 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma
82. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura
83. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: Report of a phase I-II study of weekly cisplatin/interferon alfa- 2a
84. A phase II trial of interferon alpha- 2a and carboplatin in patients with advanced malignant mesothelioma
85. Good symptom relief with palliative MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma
86. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma
87. Higher doses of alpha interferon do not increase the activity of the weekly cisplatin interferon combination in advanced malignant mesothelioma